Bookmark
Forward
QuickView for Carteolol (compound)
PubChem
| Name: | Carteolol |
|---|---|
| PubChem Compound ID: | 2583 |
| Description: | A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. |
| Molecular formula: | C16H24N2O3 |
| Molecular weight: | 292.373 g/mol |
| Synonyms: |
Carteolol hydrochloride; Carteolol; 2 (1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride; 51781-06-7; 5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydrocarbostyril monohydrochloride; OPC-1085; Abbott-43326; NSC300906; 2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-; Prestwick1_000446.
show more » |
DrugBank
Identification
| Name: | Carteolol |
|---|---|
| Name (isomeric): | DB00521 |
| Drug Type: | small molecule |
| Description: | A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. |
| Synonyms: |
Carteolol HCl; Carteolol Hydrochloride; Carteololum [INN-Latin]
|
| Brand: | Cartrol, Endak Hydrochloride, Ocupress |
| Category: | Sympatholytics, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents |
| CAS number: | 51781-06-7 |
Pharmacology
| Indication: | For the treatment of intraocular hypertension and chronic open-angle glaucoma |
|---|---|
| Pharmacology: |
Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whe...
show more » |
| Mechanism of Action: | The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade. |
| Biotransformation: | Hepatic. |
| Toxicity: | The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
